AUSTEDO XR Drug Patent Profile

When do Austedo Xr patents expire, and what generic alternatives are available?

Austedo Xr is a drug marketed by Teva and is included in one NDA. There are thirteen patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in AUSTEDO XR is deutetrabenazine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the deutetrabenazine profile page.

DrugPatentWatch^® Generic Entry Outlook for Austedo Xr

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 3, 2031. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AUSTEDO XR

US Patents:	13
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	4
Drug Prices:	Drug price information for AUSTEDO XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AUSTEDO XR
DailyMed Link:	AUSTEDO XR at DailyMed

See drug prices for AUSTEDO XR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AUSTEDO XR

NDA:

216354

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AUSTEDO XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanderbilt University Medical Center	Phase 2/Phase 3
Teva Branded Pharmaceutical Products R&D, Inc.	Phase 2/Phase 3
Fundacion Huntington Puerto Rico	Phase 1

See all AUSTEDO XR clinical trials

Paragraph IV (Patent) Challenges for AUSTEDO XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AUSTEDO XR	Extended-release Tablets	deutetrabenazine	48 mg	216354	1	2026-06-08
AUSTEDO XR	Extended-release Tablets	deutetrabenazine	6 mg, 12 mg and 24 mg	216354	1	2026-03-02

US Patents and Regulatory Information for AUSTEDO XR

AUSTEDO XR is protected by sixteen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-004	May 29, 2024		RX	Yes	No					Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-006	May 29, 2024		RX	Yes	No
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-008	Jul 1, 2024		RX	Yes	No					Y

International Patents for AUSTEDO XR

When does loss-of-exclusivity occur for AUSTEDO XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Finland

Hong Kong

Hungary

Japan

Lithuania

Netherlands

New Zealand

Norway

Poland

Portugal

San Marino

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AUSTEDO XR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	103876
Australia	2016229949
Australia	2021204740

Supplementary Protection Certificates for AUSTEDO XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3265085	C20265014	Finland
3265085	301388	Netherlands		PRODUCT NAME: DEUTETRABENAZINE; REGISTRATION NO/DATE: EU/1/25/1956 20260109
3265085	PA2026523	Lithuania		PRODUCT NAME: DEUTETRABENAZINAS; REGISTRATION NO/DATE: EU/1/25/1956 20260108

Austedo XR Market Dynamics and Financial Trajectory

Last updated: August 14, 2026

Austedo XR is Teva Pharmaceuticals' once-daily extended-release formulation of deutetrabenazine, approved in the United States for chorea associated with Huntington's disease and tardive dyskinesia. Its commercial value is driven by rapid conversion from twice-daily Austedo tablets, continued growth in tardive dyskinesia diagnosis and treatment, and Teva's ability to defend its deutetrabenazine patent estate against generic competition.

Teva reported Austedo net sales of approximately $1.2 billion in 2023, up from roughly $700 million in 2022. The product reached approximately $1.6 billion in 2024, according to Teva's annual reporting. Austedo has become one of Teva's most important growth products and is central to the company's branded pharmaceutical portfolio.

What is Austedo XR and how does it compare with Austedo tablets?

Austedo XR contains deutetrabenazine, a vesicular monoamine transporter 2 inhibitor. The product reduces abnormal involuntary movements by lowering synaptic dopamine availability.

Product	Active ingredient	Dosing profile	FDA indications	Commercial role
Austedo tablets	Deutetrabenazine	Twice daily, with some regimens requiring more frequent administration	Tardive dyskinesia and Huntington's disease chorea	Original franchise
Austedo XR	Deutetrabenazine	Once daily	Tardive dyskinesia and Huntington's disease chorea	Franchise conversion and adherence product
Ingrezza	Valbenazine	Once daily	Tardive dyskinesia and chorea associated with Huntington's disease	Primary branded competitor
Xenazine and generic tetrabenazine	Tetrabenazine	Multiple daily doses	Huntington's disease chorea	Lower-cost alternatives

Austedo XR was designed to preserve the clinical profile of deutetrabenazine while reducing dosing frequency. Once-daily administration gives Teva a commercial defense against Ingrezza, which already had a once-daily advantage in tardive dyskinesia.

How large is the Austedo XR market?

The addressable market is concentrated in two conditions: tardive dyskinesia and Huntington's disease chorea.

Tardive dyskinesia is the larger commercial market. It affects a subset of patients receiving long-term dopamine receptor-blocking therapies, particularly antipsychotics. Diagnosis remains incomplete, and treatment penetration is limited. Wider use of structured movement-disorder assessments, increased awareness among psychiatrists, and payer coverage expansion support market growth.

Huntington's disease is a smaller population market but has more specialized treatment pathways. Austedo competes with tetrabenazine and valbenazine in this setting. Treatment decisions depend on chorea severity, tolerability, dosing convenience, physician familiarity, and reimbursement.

The commercial market is therefore driven less by epidemiological expansion than by:

• Greater diagnosis of tardive dyskinesia.
• Increased treatment initiation among diagnosed patients.
• Conversion from tetrabenazine and Austedo tablets.
• Growth in long-term treatment duration.
• Prescriber preference for once-daily dosing.
• Teva's patient-support and reimbursement programs.

What are Austedo's revenue and financial trajectory?

Teva's reported Austedo sales show a rapid growth curve.

Year	Approximate Austedo net sales	Year-over-year trend	Main growth drivers
2021	Approximately $450 million	Strong growth	Tardive dyskinesia expansion
2022	Approximately $700 million	More than 50%	Higher diagnosis and treatment penetration
2023	Approximately $1.2 billion	Approximately 70%	Austedo XR launch and continued franchise growth
2024	Approximately $1.6 billion	Approximately 30% to 35%	XR conversion, market expansion, and branded demand

Sources: Teva Pharmaceutical Industries Ltd. annual reports and investor disclosures.

The 2023 result marked Austedo's transition from a high-growth specialty product into a billion-dollar franchise. The 2024 performance indicates that XR did not merely replace tablet revenue. It expanded the product's commercial platform while supporting new prescriptions and conversions.

What supports future Austedo revenue growth?

The strongest near- to medium-term drivers are:

1. XR conversion. Existing Austedo tablet patients provide a large internal conversion pool. Teva can shift patients to once-daily treatment without changing the underlying active ingredient.

2. Tardive dyskinesia penetration. Many patients with clinically significant symptoms remain untreated or undiagnosed. Growth depends on physician education and diagnosis rather than only on market share transfers.

3. Huntington's disease expansion. Although the patient population is limited, chronic treatment and specialist prescribing provide durable revenue.

4. Commercial leverage. Austedo uses an established active ingredient and existing prescriber base. Incremental sales can carry attractive margins relative to launch-stage products.

5. International expansion. The United States is the core market. Regulatory approvals and reimbursement in additional jurisdictions could increase the opportunity, but international sales are not currently comparable with the U.S. franchise.

What could slow the revenue trajectory?

Austedo growth could decelerate as:

• The installed tablet population becomes increasingly converted to XR.
• Ingrezza captures new tardive dyskinesia prescriptions.
• Generic tetrabenazine gains use in cost-sensitive channels.
• Payers impose utilization controls or require step therapy.
• Physicians view Austedo XR and Ingrezza as clinically interchangeable.
• Patent litigation creates an earlier-than-expected generic entry pathway.

Austedo's reported growth rate is unlikely to remain at its 2022-2023 level indefinitely. A transition toward mature specialty-pharmaceutical growth is more probable as the market becomes larger and the XR conversion pool declines.

How does Austedo XR compare with Ingrezza?

Austedo XR and Ingrezza are the principal branded VMAT2 inhibitors in tardive dyskinesia.

Factor	Austedo XR	Ingrezza
Manufacturer	Teva	Neurocrine Biosciences
Active ingredient	Deutetrabenazine	Valbenazine
Administration	Once daily	Once daily
Primary market	Tardive dyskinesia and Huntington's disease chorea	Tardive dyskinesia and Huntington's disease chorea
Strategic advantage	Existing Austedo franchise and tablet conversion	Early once-daily positioning and strong commercial execution
Key risk	Generic deutetrabenazine litigation and patent expiry	Valbenazine patent and exclusivity exposure
Commercial model	Teva specialty and patient-support infrastructure	Neurocrine branded specialty model

Neurocrine's Ingrezza has generated higher annual sales than Austedo in recent years, but Austedo has recorded faster percentage growth from a smaller base. The competitive contest centers on new prescriptions, formulary placement, persistence, patient assistance, and physician preference rather than a major dosing difference after the XR launch.

What FDA regulatory status does Austedo XR have?

The FDA approved Austedo tablets in 2017 for Huntington's disease chorea and later expanded the product to tardive dyskinesia. The FDA approved Austedo XR in 2023 as a once-daily formulation of deutetrabenazine. The XR product uses the same active ingredient and targets the same two approved disease areas. [1]

Austedo XR is a small-molecule prescription drug, not a biologic. Biosimilar competition is therefore not relevant. Future competition will arise through abbreviated new drug applications, patent challenges, and potential authorized-generic strategies.

The absence of a separate biologic exclusivity framework means that the key protection is the combination of:

• Listed patents.
• Regulatory exclusivity associated with approved changes, where applicable.
• Product differentiation.
• Physician and patient retention.
• Market-access contracts.

What patents protect Austedo XR and when could generic competition begin?

Austedo's protection is based on patents covering deutetrabenazine, its use in movement disorders, dosage regimens, formulations, and product presentations. Teva has disclosed issued U.S. patents and patent litigation involving generic applicants seeking to market deutetrabenazine products.

The core commercial issue is not biosimilar risk. It is whether an ANDA applicant can establish non-infringement, invalidity, or a negotiated launch date through a Paragraph IV certification.

What is the Orange Book status of Austedo?

Austedo tablets and Austedo XR are subject to FDA Orange Book patent listings. Listed patents may cover:

• Deutetrabenazine compositions.
• Dosage forms and release profiles.
• Once-daily administration.
• Treatment of tardive dyskinesia.
• Treatment of Huntington's disease chorea.
• Pharmaceutical compositions and manufacturing-related elements.

Orange Book listings can change through patent expiration, delisting, listing corrections, and litigation outcomes. Teva's publicly disclosed protection extends into the 2030s for parts of the deutetrabenazine estate, but the earliest generic launch date will depend on the specific patent claims asserted against each ANDA applicant. [2][3]

Which companies are challenging Austedo?

Generic pharmaceutical companies have pursued deutetrabenazine development and patent challenges. The relevant litigation risk is concentrated among ANDA applicants that seek approval for generic Austedo tablets or XR-equivalent products.

A Paragraph IV challenge can produce several outcomes:

1. Teva sues within the statutory period, triggering a 30-month stay of FDA approval, subject to court actions and statutory exceptions.

2. The generic applicant prevails on invalidity or non-infringement.

3. Teva prevails and preserves the listed patent barrier.

4. The parties settle with a licensed or otherwise agreed launch date.

5. The FDA approves the ANDA after patent barriers expire even if commercial launch occurs later.

The expected value of Austedo depends heavily on the first commercially meaningful generic entry date. A launch before the early 2030s would materially reduce long-term franchise value. A settlement that delays entry until late in the patent term would preserve most of the product's economic value.

What generic entry risks exist for Austedo XR?

Generic risk is medium term rather than immediate in the base case, but it is strategically material because Austedo is a concentrated revenue asset for Teva.

A generic tablet may enter before an XR-equivalent product if the relevant formulation and dosing patents differ. That could create a stepped erosion pattern:

• First, generic competition to older tablet presentations.
• Second, continued branded XR growth among patients valuing once-daily dosing.
• Third, generic XR competition after formulation patents expire or are invalidated.
• Fourth, broader substitution as payers impose generic-first requirements.

XR gives Teva a product-life-cycle management tool, but it does not create permanent market protection. Generic deutetrabenazine products could eventually compete on price, particularly in Medicaid, Medicare Part D, and managed-care formularies.

What litigation and settlement factors affect Austedo?

Austedo litigation is commercially important because Teva's revenue exposure is concentrated in a single active ingredient and therapeutic franchise. Litigation outcomes can affect:

• The duration of the 30-month stay.
• The enforceability of formulation and method-of-use claims.
• The earliest ANDA approval date.
• Whether a generic launches at risk.
• The scope of any license or settlement.
• The ability to protect XR conversion economics.

The strongest claims are usually those that directly cover the marketed formulation or dosing regimen and are difficult to design around. Method-of-use patents can be weaker if the generic label omits the patented indication, although induced-infringement arguments may preserve enforcement leverage where the use is central to the product's market.

How strong is the Austedo patent estate?

Austedo has a commercially meaningful but not unlimited patent estate.

Its strengths are:

• Multiple claim categories rather than reliance on a single compound patent.
• An established branded product with substantial revenue.
• XR differentiation that creates additional formulation and regimen claims.
• Two approved indications supporting method-of-use protection.
• Teva's scale and experience in ANDA litigation.

Its weaknesses are:

• Deutetrabenazine is a small molecule that can be challenged through conventional ANDA procedures.
• Generic applicants can contest patent validity and claim scope.
• Some patients may be readily switchable to generic tablets or competing VMAT2 inhibitors.
• Revenue concentration increases the financial effect of an adverse ruling.
• Patent expiry will eventually expose the franchise to price erosion.

The estate is stronger as a coordinated portfolio than as a single blocking right. The commercial outcome will depend on claim construction, patent-by-patent litigation results, and any settlement terms.

What is the commercial outlook for Austedo XR?

Austedo XR should remain a major Teva growth product through the remainder of the decade if Teva maintains conversion momentum and avoids early generic entry.

The base-case trajectory is:

• Continued growth from XR conversion.
• Moderating percentage growth after the tablet population is converted.
• Stable demand in Huntington's disease.
• Sustained competition with Ingrezza in tardive dyskinesia.
• Increasing payer pressure as gross sales rise.
• Eventual erosion after generic entry, with the timing determined by patent litigation and settlements.

Austedo's revenue exposure is significant. At approximately $1.6 billion in 2024 sales, the franchise represents a substantial share of Teva's branded growth. The product is therefore more important to Teva's earnings trajectory than its sales ranking alone suggests.

Key Takeaways

• Austedo XR is Teva's once-daily deutetrabenazine product for tardive dyskinesia and Huntington's disease chorea.
• Austedo sales increased from approximately $700 million in 2022 to $1.2 billion in 2023 and about $1.6 billion in 2024.
• XR conversion is the primary near-term growth engine.
• Ingrezza is the principal branded competitor; generic tetrabenazine remains a lower-cost alternative.
• Biosimilar risk does not apply because Austedo is a small-molecule drug.
• Paragraph IV litigation and Orange Book patent expiry are the central long-term risks.
• Teva's patent protection extends into the 2030s for portions of the deutetrabenazine estate, but the first generic launch date depends on claim-specific litigation and settlements.
• Austedo is likely to shift from rapid growth to mature specialty-pharmaceutical growth as XR conversion saturates.

FAQs

Does Austedo XR replace Austedo tablets?

Austedo XR is intended to provide once-daily dosing, while Austedo tablets remain available for patients whose dose or administration requirements are better managed with the immediate-release presentation.

Is Austedo XR more effective than Ingrezza?

Available regulatory approvals establish both products as treatments for tardive dyskinesia and relevant chorea indications. There is no broad head-to-head evidence establishing that one product is clinically superior across the overall patient population.

Can a generic manufacturer launch deutetrabenazine before all Austedo patents expire?

A generic may launch before all patents expire if it prevails in litigation, obtains a favorable settlement, uses a non-infringing formulation, or receives approval after relevant patents are removed or expire.

What would an early Austedo generic launch do to Teva revenue?

An early generic launch would likely cause rapid price and volume erosion in tablets, followed by pressure on XR as payers encourage substitution. The magnitude would depend on the number of entrants, product presentation, formulary rules, and whether Teva retains protected XR claims.

Is Austedo XR approved outside the United States?

Austedo's commercial value is primarily tied to the U.S. market. International expansion depends on country-specific regulatory approvals, reimbursement decisions, patent rights, and Teva's commercialization strategy.

References

1. U.S. Food and Drug Administration. (2023). Austedo XR prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. Teva Pharmaceutical Industries Ltd. (2024). Annual report for the year ended December 31, 2023. Teva.

4. Teva Pharmaceutical Industries Ltd. (2025). Annual report for the year ended December 31, 2024. Teva.

5. Neurocrine Biosciences, Inc. (2025). Annual report for the year ended December 31, 2024. Neurocrine Biosciences.